Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer
Abstract Recent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, Merchandise especially with the inability of current HER2 IHC and FISH assays to accurately determine HER2 expression in the unamplified setting.Here, we present a heavi